Nxera Pharma to Present at the 43rd Annual J.P. Morgan

Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Firm”; TSE 4565) – previously often known as Sosei Group or Sosei Heptares – proclaims that Chris Cargill, President and CEO, will current on the 43^rd Annual J.P. Morgan Healthcare Convention on Wednesday, 15 January 2025 at 3:00 p.m. PST.

Traders, analysts, members of the media and most people are invited to hearken to a dwell audio webcast of the presentation at this weblink.

Presentation slides will probably be made accessible by the investor part of the Firm’s web site.

–END–

About Nxera Pharma
Nxera Pharma (previously Sosei Heptares) is a know-how powered biopharma firm, in pursuit of latest specialty medicines to enhance the lives of sufferers with unmet wants in Japan and globally.

Along with a number of merchandise being commercialized in Japan, we’re advancing an in depth pipeline of over 30 lively applications from discovery by to late scientific stage internally and in partnership with main pharma and biotech corporations. This pipeline is concentrated on addressing main unmet wants in a few of the fastest-growing areas of medication throughout neurology, GI and immunology, metabolic problems and uncommon ailments, and leverages the ability of our distinctive and trade main GPCR-targeted structure-based drug discovery NxWave™ platform to supply a sustainable supply of best- or first-in-class candidates.

Nxera employs over 350 gifted individuals at key places in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Inventory Alternate (ticker: 4565).

For extra data, please go to www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera – Media and Investor Relations
Kentaro Tahara, VP Investor Relations and Company Technique
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Supervisor
+81 (0)3 5210 3399 | +44 (0)1223 949390 |[email protected]

MEDiSTRAVA (for Worldwide Media)
Mark Swallow, Frazer Corridor, Erica Hollingsworth
+44 (0)203 928 6900 | [email protected]

Ahead-looking statements
This press launch comprises forward-looking statements, together with statements concerning the discovery, growth, and commercialization of merchandise. Numerous dangers could trigger Nxera Pharma Group’s precise outcomes to vary materially from these expressed or implied by the ahead trying statements, together with: adversarial ends in scientific growth applications; failure to acquire patent safety for innovations; industrial limitations imposed by patents owned or managed by third events; dependence upon strategic alliance companions to develop and commercialize services and products; difficulties or delays in acquiring regulatory approvals to market services and products ensuing from growth efforts; the requirement for substantial funding to conduct analysis and growth and to broaden commercialization actions; and product initiatives by opponents. On account of these elements, potential traders are cautioned to not depend on any forward-looking statements. We disclaim any intention or obligation to replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case.